The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response
Open accessAbstract
We appreciate the opportunity to respond to the comments provided by Ferrara and colleagues.First, Ferrara and colleagues state that “a minority of intratumoral FOXP3+CD4+ T cells (regulatory T cells [T regs]) express membrane CTLA-4”. This statement is in contrast to our previous findings demonstrating that a majority (∼60%–90%) of murine intratumoral FOXP3+CD4+ T cells express cell surface CTLA-4 (1). In addition, Ferrara and colleagues referenced a study by Marabelle and colleagues, who have shown in another murine model that approximately 50% intratumoral FOXP3+CD4+ T cells express cell surface CTLA-4 (2). Also, we reevaluated our CyTOF data from paired pre- and post-treatment human melanoma tissues as described in Supplementary Fig. S6 of our paper (3), and we generated additional data (Fig. 1), which did not show any evidence for depletion of FOXP3+CD4+ Tregs expressing CTLA-4 (intracellular and membrane-bound). Furthermore, since FOXP3 is used to identify Tregs, and the majority of FOXP3+CD4+ T cells express CTLA-4, we relied on FOXP3 staining in our IHC studies to determine whether Tregs were depleted by anti–CTLA-4 therapy.In addition, Ferrara and colleagues suggest that intratumoral Treg depletion may be more prevalent in responders versus nonresponders. However, our previously published data evaluating tremelimumab-treated melanoma samples did not show any significant difference in the density of intratumoral FOXP3+ cells between responders and nonresponders (4). Likewise, we evaluated 11 patients from our published manuscript (3) to correlate the density of intratumoral FOXP3+ cells with clinical response to ipilimumab in post-treatment melanoma samples. As shown in Fig. 2, we did not observe any difference in the density of intratumoral FOXP3+ cells between responders (N = 4) and nonresponders (N = 7).Ferrara and colleagues also referenced Romano and colleagues (5), who evaluated intratumoral FOXP3+ cells in pre- and post-ipilimumab melanoma samples (5 responders and 8 non-responders). Their conclusion was that anti–CTLA-4 therapy depletes intratumoral Tregs in responders. However, it should be noted that Romano and colleagues evaluated FOXP3+ cells as a percentage of “total” tumor-infiltrating lymphocytes, which consists of subsets such as effector CD4+ and CD8+ T cells. Therefore, in the setting of anti–CTLA-4 therapy, which tends to increase the “total” number of tumor-infiltrating lymphocytes, especially in responders, the actual number of FOXP3+ cells may not change, but the percentage of FOXP3+ cells may appear to be less. We discussed this issue in our paper (3), and for this reason we chose to quantify intratumoral immune subpopulations using density rather than percentage.Furthermore, Ferrara and colleagues emphasize that prior studies in in vivo mouse models have shown that Treg depletion is rapid (within days) following anti–CTLA-4 therapy (1, 5–7). This is true in mouse models where the murine antibodies have a short half-life, but the human anti–CTLA-4 antibodies have a much longer half-life and different levels of penetration into human tumors, which makes it unlikely to have similar kinetics in patients. Moreover, to address the issue of early depletion of Tregs, we would need to consider the ethical ramifications of multiple invasive procedures within short intervals to obtain longitudinal tumor samples from patients. We addressed this issue as best as we could as shown in Supplementary Fig. S4 of our published manuscript (3), and we did not observe a correlation between timing of post-treatment biopsy and the density of intratumoral FOXP3+ cells.Finally, we do agree with Ferrara and colleagues that future clinical studies should include proportion and phenotype of all antibody-dependent cellular cytotoxicity performing cells and their FCγR repertoire within the tumor microenvironment. However, this will likely be difficult in human studies given the limited amounts of tissue available from tumor biopsies.See the original Letter to the Editor, p. 3468S.K. Subudhi reports receiving speakers bureau honoraria from Valeant Pharmaceuticals International and the University of Texas Health Science Center at Taylor; holds ownership interest (including patents) in Apricity Health LLC; and is a consultant/advisory board member for Bayer HealthCare Pharmaceuticals, Dendreon, and Driver Inc. J.A. Wargo reports receiving speakers bureau honoraria from Dava Oncology, Illumina, Roche Genentech, Bristol-Myers Squibb, Merck, Gilead, MedImmune, and PHE; and is a consultant/advisory board member for Novartis, Bristol-Myers Squibb, AstraZeneca, Roche Genentech, and Merck. J.P. Allison holds ownership interest (including patents) in Jounce, Neon, Forty-Seven, ImaginAb, Tvardi Therapeutics, Constellation Pharmaceuticals, BioAtla, Polaris Pharmaceuticals, Hummingbird Bioscience, Merck, Amgen, Aparicity Therapeutics; has immediate family members who hold ownership interest in Jounce, Neon, Constellatio
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationTGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Metadata
- Authors
- Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P.
- Venue
- Clinical Cancer Research
- Published
- 2019-06-01
- Volume
- 25
- Issue
- 11
- Pages
- 3469-3470
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2883858361
- Cited by
- 312
- References
- 36
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0402
- The paper
- Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019). Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.